Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 10/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4532271 | 0.82 | NR1H4 (0.42) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4523300 | 0.81 | NR1H4 (0.52) | NR1H4ESR1 | |
| SCHEMBL4565180 | 0.80 | NR1H4 (0.44) | ALDH1A1NR1H4ESR1NR3C1PGR | |
| SCHEMBL4525330 | 0.79 | PABPC1 (0.36) | ALDH1A1NR1H4ESR1NR3C1PGR | |
| SCHEMBL4536855 | 0.78 | NR1H4 (0.36) | ALDH1A1NR1H4ESR1NR3C1PGR | |
| SCHEMBL4528374 | 0.78 | NR1H4 (0.38) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4520698 | 0.78 | NR1H4 (0.40) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4526606 | 0.78 | NR1H4 (0.38) | ALDH1A1NR1H4 | |
| SCHEMBL4521015 | 0.77 | ALDH1A1 (0.43) | ALDH1A1NR1H4 | |
| SCHEMBL4533951 | 0.77 | NR1H4 (0.42) | NR1H4ESR1NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | NR1H4, NR1I2, GPBAR1 | ALDH1A1 622/4885NR1H4 1/4885HTR2A 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.